Bortezomib TZF 3,5 mg pulveris injekciju šķīduma pagatavošanai Latvia - Latvian - Zāļu valsts aģentūra

bortezomib tzf 3,5 mg pulveris injekciju šķīduma pagatavošanai

tarchomin pharmaceutical works "polfa" s.a., poland - bortezomibs - pulveris injekciju šķīduma pagatavošanai - 3,5 mg

Tevimbra European Union - Latvian - EMA (European Medicines Agency)

tevimbra

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastiski līdzekļi - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.